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ABSTRACT: 
Osteoarthritis is a multifarious joint disease and is caused by inflammatory mediators, along with a procedure of wear and tear of 
cartilage. Osteoarthritis outcome in cartilage degradation, synovial inflammation, subchondral bone eburnation, degeneration of 
menisci, and capsular hypertrophy, which takes part in the pathogenesis of Osteoarthritis. Pain is the leading symptom of 
Osteoarthritis. However the precise mechanism causing pain is multifactorial and is still not well known. Viscosupplementation 
with intraarticular hylauronic acid promotes chondrocyte hyaluronic acid synthesis and prevents the additional cartilage 
degradation and may possible help to promote the cartilage regeneration. It is also postulated to diminish the production of 
inflammatory mediators and matrix metalloproteinase involved in Osteoarthritis. Viscosupplementation decline osteoarthritis 
symptoms in early to judicious Osteoarthritis, and improves functional outcome, if other conservative treatment modalities are 
ineffective. Hyaluronic acid (HA) is the major constituent of a 1--‐2μm layer on the surface of articular cartilage; it is also a major 
constituent of synovial fluid. HA has many properties including exerting an anti-inflammatory effect, it acts as a lubricant when 
movements in the joint are slow and as a shock absorber when movements are fast effect. Viscosupplementation relieves the 
symptoms of osteoarthritis of the knee, and this therapeutic effect may last several weeks. However, it is apparently not much 
greater than that of placebo and, according to some studies, it barely reaches clinical significance. Its pain-relieving effect seems 
comparable to that of other non-surgical options. The modest clinical benefit of viscosupplementation may never be great enough 
to outweigh its disadvantages, which include slow onset of action, the need for several weekly injections, the low but present risk 
of adverse reactions and the relatively high cost of this treatment. It helps in improving the function in early osteoarthritis knee 
joint and might delay the need for future knee surgery 
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INTRODUCTION 
Osteoarthritis is the major source of functional 
disability and reduced autonomy in elderly adults. It 
involves an estimated 21 million people in the United 
States and represents an important economic problem. 
The present mainstay of treatment in osteoarthritis is 
exercise and non-steroidal anti-inflammatory drugs 
(NSAIDs) to control pain and stiffness, but neither has 
the ability to modify the course of the disease. The 
revision rates in the long term results of THA have been 
estimated 33 to 45%. Generally young adults suffer 
from secondary rather than primary osteoarthritis. 
Several troubles at birth or later during growth may 
injure the hip joint producing disadvantageous 
biomechanics, which cause cartilage breakdown. 
Osteoarthritis is the most common form of chronic 
arthritis worldwide. Hyaluronan and hylan products 
provide opportunity to treat OA in individual knee 
joints. 
1,2
 Osteoarthritis mostly affects the cartilage. 
Cartilage is the tissue that covers the ends of bones in a 
joint. When healthy, cartilage allows bones to glide 
over one another and provides a "shock absorber" 
function. The normal knee joint also contains a small 
amount of fluid called synovial fluid, which is a thick, 
gel-like substance that cushions the joint and provides 
lubrication to reduce friction. In osteoarthritis, the 
surface layer of cartilage breaks down and wears away. 
Adding to the problem, the synovial fluid in your knees 
loses its ability to lubricate the joint. This combination 
causes pain and stiffness, limitation of joint motion, and 
some inflammation in your knees. 
3-7
 
Non-pharmacological modalities are important and 
include patient education, exercises, weight reduction, 
sometimes walking with support (crutches) during acute 
phase, bracing of the knees, shoe modifications and 
modification of insoles to provide varus or valgus thrust 
to knee. Local heat and cold, massage, acupuncture, and 
electromagnetic therapy are also found to be helpful in 
subset of patients. Pharmacologic treatment is mainstay 
and includes mostly acetaminophen or paracetamol, 
non-steroidal anti-inflammatory drugs (NSAIDs), 
sometimes opioids, and drugs which slow down 
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cartilage degeneration like glucosamine and chondroitin 
sulphate. These drugs which slow down cartilage 
degeneration are used in oral form, and are usually 
slow-acting drugs (glucosamine and chondroitin 
sulphate) and if orally administered, these drugs are 
usually not much effective. Intraarticular (IA) injection 
with corticosteroids, Hyaluronic acid (HA) and recently 
platelet rich plasma (PRP) is the last on list of non 
operative management. Intraarticular Hyaluronic acid 
(HA) has the ability of restoring normalization of 
synovial fluid viscoelasticity and also activates tissue 
repair process in articular cartilage. 
8-10
 
In its early stages, arthritis of the knee is treated with 
nonsurgical methods. Your doctor may recommend a 
range of treatments, including:  
 Changes in activity level 
 Weight loss 
 Pain relievers, such as acetaminophen or 
nonsteroidal anti-inflammatory drugs (NSAIDs) 
like ibuprofen  
 Physical therapy 
 Corticosteroid injections 
Another treatment option is a procedure called 
viscosupplementation. If you have tried all other 
nonsurgical treatment methods and your pain continues 
to limit your activities, viscosupplementation may be an 
option.  
The actual changes to the joint surfaces can be seen 
below: 
 
 
 
VISCOSUPPLEMENTATION: 
Hyaluronic acid is a naturally occurring substance 
present in the synovial fluid of your joints. In your 
knees, synovial fluid, a thick gel-like liquid, helps 
cushion your joint and absorb the shock of walking, 
running, twisting, and turning. People with 
osteoarthritis of the knee have lower levels of 
hyaluronic acid in their synovial fluid. Therefore, their 
joints are less “greased” and less able to protect the 
bones and cartilage from damage and destruction. 
Viscosupplementation, a popular treatment for 
Osteoarthritis of the knee, injects hyaluronic acid (also 
called hyaluron and hyaluronate) into the affected knee 
in order to hopefully return some mobility to the joint. 
In this procedure, a gel-like fluid called hyaluronic acid 
is injected into the knee joint. Hyaluronic acid is a 
naturally occurring substance found in the synovial 
fluid surrounding joints. It acts as a lubricant to enable 
bones to move smoothly over each other and as a shock 
absorber for joint loads. People with osteoarthritis have 
a lower-than-normal concentration of hyaluronic acid in 
their joints. The theory is that adding hyaluronic acid to 
the arthritic joint will facilitate movement and reduce 
pain. The most recent research, however, has not found 
viscosupplementation to be effective at significantly 
reducing pain or improving function. Although some 
patients report pain relief with the procedure, some 
people are not helped by the injections. 
Viscosupplementation was first used in Europe and 
Asia, and was approved by the U.S. Food and Drug 
Administration in 1997. Several preparations of 
hyaluronic acid are now commercially available.  
MECHANISM OF ACTION 
Hyaluronic acid (HA) is a glycosaminoglycan which is 
naturally occurring and is a normal component of 
synovial fluid and the cartilage matrix. Moreover, cells 
from synovium, chondrocytes and fibroblasts synthesis 
the hyaluronic acid and then secrete it into the joint. 
Hyaluronic acid enhances the joint function due to 
normalization of synovial fluid viscoelasticity, and acts 
as a lubricant and also a shock absorber in nature during 
the different phases of joint movements. It also has the 
ability reduces stress on hyaline cartilage and also tends 
to reduce friction on joint cartilage. Hyaluronic acid is 
also a important constituent of proteoglycans of the 
extracellular matrix. Hyaluronic acid also is postulated 
to be anti inflammatory, mild analgesic and activates 
the tissue repair process of the articular hyaline 
cartilage.
11- 14
 
ADVANTAGES: 
 Safe and effective 
 Improves pateint assessed pain 
 Low rate of complications 
 Ha products of higher molecular weight may be 
more effecatious than those of lower molecular 
weight 
DISADVANTAGES: 
The disadvantages of viscosupplementation were that 
patients with less recent diagnoses were less likely to 
advantage than those with more current diagnoses. In 
other words, patients with more strict radiographic 
changes also have responded less. The potential adverse 
events associated with viscosupplementation include 
joint effusion, joint swelling, arthralgia, joint warmth, 
and injection-site erythema. 
Synvisc injections provide relief through 
"viscosupplementation". The goal is to restore the 
natural elasticity and viscous properties of synovial 
fluid. Synvisc is one of the hyaluronates used in 
viscosupplementation, other hyaluronates include: 
 Euflexxa 
 Hyalgan 
 Orthovisc 
 Supartz 
Kapoor et al                                     Journal of Drug Delivery & Therapeutics. 2016; 6(4):73-78                                 75 
© 2011-16, JDDT. All Rights Reserved                                   ISSN: 2250-1177                                  CODEN (USA): JDDTAO 
Euflexxa 
Euflexxa is one of the hyaluronates used in 
viscosupplementation. Euflexxa is a treatment for 
osteoarthritis which is injected directly into the knee 
joint. Euflexxa is the first hyaluronic acid that is not 
derived from an avian source. 
Euflexxa is a solution of highly purified hyaluronan 
(also called hyaluronic acid or sodium hyaluronate) in 
saline. The hyaluronan in Euflexxa is extracted from 
bacterial cells. It is the first non-avian derived 
hyaluronan. 
Euflexxa is one of the hyaluronates used in 
viscosupplementation. Euflexxa is injected directly into 
the knee joint to restore the cushioning and lubricating 
properties of normal synovial fluid (i.e., joint fluid). 
Knee joints affected by osteoarthritis lose their 
lubricating properties. 
Indication for Euflexxa: 
Euflexxa was approved by the U.S. FDA on December 
3, 2004 for the treatment of knee pain associated with 
osteoarthritis in patients who have failed to respond to 
more conservative non-drug therapy (e.g., physical 
therapy) and to simple analgesics, such as 
acetaminophen. Euflexxa is administered as a series of 
three weekly intra-articular injections. 
Contraindications for Euflexxa: 
People with a known hypersensitivity to hyaluronan 
products should not be treated with Euflexxa. Also, 
people with an infection in the knee joint, other 
infection, or skin disease in the area where the injection 
would occur should not be treated with Euflexxa. 
Common Side Effects and Adverse Events: 
The most common adverse events associated with 
Euflexxa treatment during clinical studies included 
arthralgia (joint pain), back pain, pain in the arms or 
legs, musculoskeletal pain, and joint swelling. Adverse 
events that may occur with any intra-articular injection 
include arthralgia, joint swelling, joint effusion, 
injection site pain, and arthritis. 
Precautions and Warnings: 
After receiving an intra-articular injection of Euflexxa, 
as with any joint injection, it is recommended that the 
patient avoid strenuous activities or prolonged 
weightbearing activities for 48 hours. Also, it should be 
noted that pain or swelling may occur after the 
injection, but will diminish after a relatively short time 
period. 
Hyalgan: 
Hyalgan is a viscous solution that contains purified 
natural sodium hyaluronate (Hyalectin) in physiological 
saline. Hyalgan is one of the hyaluronates used in 
viscosupplementation -- a treatment that involves 
injecting a gel-like substance (hyaluronate) into a joint 
to supplement the viscous properties of synovial fluid. 
The injected viscosupplement helps to cushion the joint 
and provides lubrication to reduce friction that occurs 
with movement. With osteoarthritis, synovial fluid loses 
its lubricating properties and the goal of 
viscosupplementation is to restore those properties. 
Indications for Hyalgan: 
Hyalgan was approved by the U.S. Food and Drug 
Administration (FDA) on May 28, 1997 as a treatment 
option for knee osteoarthritis. It is considered a 
treatment, not a drug. The sodium hyaluronate in 
Hyalgan is extracted from rooster combs. Hyalgan is 
indicated for patients with pain related to knee 
osteoarthritis who have failed to achieve relief with 
conservative non-drug treatments and with simple 
analgesics, such as acetaminophen 
Administration of Hyalgan: 
Hyalgan is an intra-articular injection typically given 
once a week, one week apart, for a total of 5 injections. 
Some patients may achieve a successful outcome after 3 
weekly cycles, based on study results of patients who 
received 3 injections and then were followed for 60 
days. 
Precautions and Warnings: 
There are several precautions and warnings associated 
with Hyalgan intra-articular injections: 
 The safety and effectiveness of Hyalgan in joints 
other than the knee has not been studied. 
 If a patient has allergies to avian proteins, feathers, 
or eggs, injection should be done with caution. 
 There may be pain or swelling with the injection 
that will subside. It is advised, as with all intra-
articular injections, that patients not participate in 
strenuous or weightbearing activity for 48 hours 
after the injection. 
 The safety and effectiveness of Hyalgan injections 
has not been established in pregnant women, nor in 
lactating women. Its use has not been studied in 
children. 
SIDE EFFECTS AND ADVERSE EVENTS: 
Common side effects associated with Hyalgan injetions 
include gastrointestinal issues, injection site pain, knee 
swelling or effusion, local skin rash, itching, and 
headache. Most side effects are injection site reactions 
which subside after a few days, especially with rest and 
application of ice. Attention must be paid to symptoms 
which persist and may be indicative of something more 
severe, such as infection or systemic allergic reactions. 
Such severe adverse events are considered rare. 
Synvisc: 
Synvisc is one of the hyaluronates used in 
viscosupplementation. Synvisc is a treatment for 
osteoarthritis which is injected directly into the knee 
joint. Synvisc injections are approved for the treatment 
of osteoarthritis of the knee in those who have failed to 
respond to more conservative therapy.  
Synvisc-One (hylan G-F 20): 
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Synvisc-One is the only viscosupplement approved as a 
one-dose injection. The FDA indicates that this 
viscosupplement is designed to provide up to six 
months of OA relief after just one injection. The most 
common side effects of a Synvisc-One injection include 
swelling around the affected joint and pain and stiffness 
in the joint. 
Synvisc (hylan G-F 20): 
Unlike Synvisc-One, Synvisc requires three injections 
of hyaluronic acid. The effects of the injection can last 
as long as six months. The side effects of Synvisc are 
similar to the side effects of Synvisc-One — pain, 
swelling, and fluid buildup around the affected joint. 
Orthovisc: 
Orthovisc is one of the hyaluronates used in 
viscosupplementation. Orthovisc is a treatment for 
osteoarthritis which is injected directly into the knee 
joint. 
Supartz (sodium hyaluronate): 
This viscosupplement is given as a three- or five-dose 
injection. A three-dose injection series provides relief 
for up to six months. A greater number of injections 
may provide a longer window of pain relief. The most 
common side effects of a Supartz injection include pain, 
effusion (swelling in the joint), redness and bruising at 
the joint, and injection site pain. 
THE MORE SERIOUS SIDE EFFECTS OF 
VISCOSUPPLEMENTS 
Typical side effects of viscosupplement injections are 
mild — redness, swelling, skin irritation at the injection 
site — but serious side effects are possible. Contact 
your doctor’s office immediately if you begin 
experiencing any of the following side effects:  
 closing of the throat 
 difficulty breathing 
 hives 
 swelling of the lips, tongue, or face 
You may be having a more serious reaction to the 
injection and need medical attention.  
Long term perspective: 
Viscosupplements are new to the treatment scene. We 
know how they work in the short term, but their 
effectiveness over longer periods of time isn’t yet 
known. Specifically, doctors are uncertain how the use 
of viscosupplements over the course of a person’s life 
will affect health. Research is also not clear on how 
viscosupplementation affects the long-term trajectory of 
osteoarthiritis of the knee. While it does provide 
comfort and pain relief for some people with mild to 
moderate osteoarthiritis, it may not prevent or even 
delay the likelihood that a patient will need knee 
replacement surgery at a later point in their life. 
Effectiveness: 
When successful, viscosupplementation can provide 
knee osteoarthritis pain relief for 3 months or even a 
year, with the greatest pain relief typically found 
between 5 and 13 weeks.  
Hyaluronic Acid vs. Hylans: 
Hyaluronic acid, which is naturally found in joint fluid, 
is sometimes referred to as hyaluronan, hyaluronate 
or HA. 
Substances called hylans are derivatives of hyaluronic 
acid, meaning the two are chemically similar. The term 
viscosupplementation includes hyaluronic acid as well 
as hylan injections. Both types of injection therapies 
aim to decrease pain and improve joint movement.
 
Table 1: Viscosupplementation Dosing 
Drug  Dose 
Euflexxa (1% sodium hyaluronate) 20 mg once a week (1 week apart) for a total of 3 injections. 
Gel-Syn (0.84% sodium hyaluronate) 16.8 mg once a week (1 week apart) for a total of 3 injections 
GenVisc 850 (sodium hyaluronate) 25 mg once a week (1 week apart) for a total of 5 injections 
Hyalgan (sodium hyaluronate) 20 mg once a week (1 week apart) for a total of 5 injections. 
Monovisc (high molecular weight 
hyaluronan) 
88 mg (4 ml) one time injection 
Orthovisc (high molecular weight 
hyaluronan) 
30 mg once a week (1 week apart) for a total of 3 to 4 
injections. 
Supartz (sodium hyaluronate) 10 mg once a week (1 week apart) for a total of 5 injections. 
Synvisc One (Hylan G-F 20) 48 mg one time injection. 
Synvisc (Hylan G-F 20) 16 mg once a week (1 week apart) for a total of 3 injections. 
Gel-One (Cross-linked Hyaluronate) 30 mg (3 ml) one time injection 
 
Adverse effects of viscosupplementation injections: 
The most commonly reported side effects associated 
with the injections are temporary injection-site pain; 
swelling, heat, or redness; rash and itching; bruising 
around the joint; and fluid accumulation in the injected 
knee. These reactions are usually mild and don't last 
long. As with steroid injections, infection and bleeding 
are also rare complications.[15] 
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REPORTED WORK ON VISCOSUPPLEMETS: 
 Vignon (2005) concluded that to date, in the 
absence of placebo-controlled studies, the 
effectiveness of intra-articular injections of 
hyaluronic acid or its derivatives in the 
symptomatic treatment of hip OA can not be 
determined conclusively.  Nevertheless the 
published data suggest that viscosupplementation 
may be effective.  These researchers stated that 
double-blind, controlled studies are needed to 
confirm these data, before viscosupplementation 
should be included into the treatment paradigm for 
patients with hip OA.
16
 
 Migliore et al (2006) reported the effects of hylan 
G-F 20 administered through ultrasound (US)-
guided intra-articular (IA) injections in patients 
with symptomatic hip OA.  They treated 30 
patients with symptomatic hip OA.  Under US 
guidance, 7 patients received 1 injection, 21 
patients had 2 injections, and 2 patients received 3 
injections, each with 2 ml of hylan G-F 
20.  Lequesne index, visual analog scale (VAS) 
scale of hip pain, and NSAID consumption were 
evaluated at baseline as well as 2 and 6 months 
after the beginning of the treatment.  No systemic 
adverse events were observed.
17
 
 Van den Bekerom et al (2008) evaluated the 
effectiveness of viscosupplementation in 
the treatment of hip OA.  A total of 16 articles 
concerning the effectiveness of a total of 509 
patients undergoing viscosupplementation for hip 
OA were included -- 12 European studies, 3 
Turkish studies and 1 American study with levels 
of evidence ranging from I to IV evaluated the 
following products: Hylan G-F 20, Hyalgan, 
Ostenil, Durolane, Fermatron and 
Orthovisc.  Heterogeneity of included studies did 
not allow pooled analysis of data.  The authors 
noted that despite the relatively low level of 
evidence of the included 
studies, viscosupplementation performed under 
fluoroscopic or ultrasound guidance seems an 
effective treatment and may be an alternative 
treatment of hip OA.
18
 
 Carpenter and Motley (2008) noted that although 
anecdotal data exist, no long-term studies 
regarding the use of viscosupplementation in the 
ankle have been published to date.  These 
researchers compared pain reduction following 
ankle arthroscopy versus that following ankle 
arthroscopy combined with weekly intra-articular 
instillation of hylan G-F 20 during the first 3 post-
operative weeks.  They found that both treatment 
groups experienced statistically significantly 
decreased pain following the intervention (p = 
0.002 and p = 0.0009 for the arthroscopy alone and 
arthroscopy plus hylan groups, respectively), and 
that those who received 3 intra-articular injections 
of hylan G-F 20 following ankle arthroscopy 
improved statistically significantly (p = 0.0014) 
more than did those who underwent arthroscopy as 
a sole therapy. 
19
 
 Cleary and colleagues (2008) examined the 
potential effectiveness of HA injection therapy in 
the treatment of lumbar facet joint arthritis.  A 
total of13 patients with symptomatic lumbar facet 
joint arthritis who met the inclusion criteria were 
prospectively recruited.  Pre-treatment evaluation 
of patients was by questionnaire, including the 
VAS and Oswestry Disability Questionnaire.  A 
single injection of HA into affected facet joints 
was then performed, with correct placement 
confirmed on fluoroscopy.  Patients were similarly 
evaluated 6 weeks after treatment. 
20
 
 Conrozier et al (2009) assessed the effectiveness 
and tolerability of a single intra-articular injection 
of non-animal-stabilized HA (NASHA) in patients 
treated for symptomatic hip OA (HOA).  A total of 
40 patients suffering from HOA were treated by a 
single intra-articular injection of NASHA in the 
painful hip under fluoroscopy. 
21
 
 Vanelli and associates (2010) evaluated the safety 
and effectiveness of intra-articular polynucleotides 
(PN) gel injections in the treatment of knee OA 
associated with persistent knee pain.  A total of 60 
patients were enrolled and randomized to receive 
intra-articular polynucleotides (n = 30) or 
hyaluronan (n = 30); patients received 5 weekly 
intra-articular knee injections and the follow-up 
period was 3 months after the end of treatment. 
22
 
 Manfredini and colleagues (2010) examined the 
clinical studies on the use of HA injections to treat 
temporomandibular joint (TMJ) disorders 
performed over the last decade.  The selected 
papers were assessed according to a structured 
reading of articles format, which provided that the 
study design was methodologically evaluated in 
relation to 4 main issues: (i) population, (ii) 
intervention, (iii) comparison, and (iv) 
outcome.  A total of 19 papers were selected for 
inclusion in the review, 12 dealt with the use of 
HA in TMJ disk displacements and 7 dealt with 
inflammatory-degenerative disorders. 
23
 
CONCLUSION: 
The price of injection is also a chief issue in India for 
the multiple doses over the NSAIDS, steroid and 
Platelet rich plasma intraarticular injections. The 
Hyaluronic acid (HA) injections had a good safety 
profile with fewer local reactions. Most of the subjects 
coming to hospital wherein grade I and II of OA knee. 
3 weekly doses of 2ml HA is found to be potentially 
effective in terms of symptomatic pain relief and 
functional outcome. This may also prolongs the need of 
total knee arthroplasty in patient with early OA. But 
long term study is needed to evaluate its role in 
cartilage regeneration 
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